Ken Griffin Aldeyra Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$3.19 - $6.32 $11,484 - $22,752	3,600 Added 4.09%	91,700 $494,000
Q2 2024 Aug 14, 2024	BUY	$3.25 - $4.72 $13,325 - $19,352	4,100 Added 4.88%	88,100 $291,000
Q1 2024 May 15, 2024	BUY	$2.77 - $4.22 $171,463 - $261,217	61,900 Added 280.09%	84,000 $274,000
Q4 2023 Feb 14, 2024	BUY	$1.47 - $6.06 $19,992 - $82,416	13,600 Added 160.0%	22,100 $77,000
Q3 2023 Nov 14, 2023	SELL	$6.11 - $8.16 $131,976 - $176,256	-21,600 Reduced 71.76%	8,500 $56,000
Q2 2023 Aug 14, 2023	SELL	$7.11 - $11.89 $352,656 - $589,744	-49,600 Reduced 62.23%	30,100 $252,000
Q1 2023 May 15, 2023	BUY	$5.77 - $9.93 $133,287 - $229,383	23,100 Added 40.81%	79,700 $791,000
Q4 2022 Feb 14, 2023	SELL	$5.08 - $7.09 $75,692 - $105,641	-14,900 Reduced 20.84%	56,600 $393,000
Q3 2022 Nov 14, 2022	BUY	$3.8 - $7.74 $271,700 - $553,410	71,500 New	71,500 $382,000

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $280M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.